Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Of those, 1,482 (37%) who initiated injectable semaglutide between March 2018 and November 2023 met all inclusion criteria: At least 2 semaglutide prescriptions 3 months apart (to be reasonably confident of ongoing use) No other GLP-1 receptor agonist within 6 months before semaglutide initiation or within the first 3 months of semaglutide use No prescription for oral semaglutide (Rybelsus) Baseline BMI 27 kg/m2, based on the most recent BMI measurement available within 6 months before (or on) the semaglutide start date At least 1 follow-up BMI measurement available 3-12 months after the semaglutide start date Among all weight measurements within up to 12 months after semaglutide initiation, BMI was calculated as weight in kilograms divided by the square of height in meters
This product includes a downloadable test report or certificate file where available
Regular exercise complements semaglutides effects, enhancing weight loss and improving cardiovascular health
Accessing Weight Loss Medicines Safely Through UK Healthcare NICE-approved options including semaglutide (Wegovy) and tirzepatide (Zepbound) are available through NHS specialist weight management services or CQC- and GPhC-regulated private providers following a clinical consultation
US$ 28.83
US$ 28.89
US$ 26.18
US$ 22.50
US$ 24.37
US$ 28.01
